Hepatitis: Disease and Pipeline Analysis

“Nonalcoholic steatohepatitis (NASH) Pipeline Analysis” gives comprehensive insight on the various drugs being developed for the treatment of NASH. The report covers all the drugs being developed in various phases (Discovery, Preclinical & Clinical development). The pipeline focuses on novel medicines covering small molecules, monoclonal antibodies, Recombinant proteins and RNA-based therapeutics, but excludes Off-label, symptom relief drugs, generic combinations. The report also covers hot targets in research for NASH treatments and disease progression biomarkers.

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Nonalcoholic steatohepatitis (NASH) Drug market. The report also provides strategic insights on medicines that are likely to have an impact on future NASH treatment space.

• Key Findings:

• The global NASH market is estimated to be $330 million by 2018 with the approval of new drugs and is expected to grow at a CAGR of high-range double digit from 2018 to 2024 to reach $xx billion by 2024
• Factors contributing to the market growth include, Launch of approved drugs, technological advancements leading to emergence of novel therapeutics & mechanisms, increase in investments, increasing incidence of NAFLD, NASH, diabetes, obesity & cardiac diseases, alteration in lifestyle and high unmet needs & lack of approved drugs.
• IQ4I analysis indicates that 36% of candidates are in Pre-clinical stage followed by 33% in PII clinical
• In addition to small molecules, there is growing interest among researchers on large molecules and novel therapies, such as
  • RNA-based therapy
  • Monoclonal antibody-based therapy
  • Recombinant proteins